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The host defense response to influenza infection is complex. Specific humoral 
antibodies develop to the strain-specific surface antigens, the hemagglutinin 
and the neuraminidase, and to the internal antigens (matrix and nucleoprotein) 
which are common to all influenza A viruses (1). Antibodies to the hemaggluti- 
nin,  which is  the  major surface antigen,  neutralize viral  infectivity (2). In 
addition to  antibodies which have been detected against virion antigens,  a 
cytotoxic T-cell response with specificity against the viral hemagglutinin on 
influenza-infected target cells (3-5) has been recently described. A more cross- 
reactive cytotoxic T-cell response has also been observed when a  nonpermis- 
sively infected target cell is  used in  cytotoxicity assays  (6,  7).  The present 
report describes the development during influenza infection and after vaccina- 
tion of a  cytolytic humoral antibody response which is directed against the 
hemagglutinin on infected target cells. This antibody-mediated lysis of infected 
cells is complement dependent, as has been reported with other virus infections 
(8-11). 
Materials and Methods 
Viruses.  The  A  Equine-1  Detroit/3/65  virus  (HeqlNeql),  and  the  H3Neql  and  HeqlN2 
recombinants of  this  virus with A/Port Chalmers (H3N2) were provided by Dr. Brian Murphy of 
the National Institutes  of  Health, Betheeda, Md. These viruses had not been adapted by mouse 
passage. Recombinant MRC-9 (H3N2) derived from A/Port Chalmers/1/73 and A/PR/8/34 (HON1) 
was provided  by Dr. Geoffrey Schild of the National Institute  for Biological Standards and 
Control, Holly Hill,  England, and had been adapted for growth in mice by repeated intranasal 
passage of  infected  lung tissue.  Other influenza A and B strains  were obtained from the Bureau 
of  Biologics  and have been described earlier  (3,  4).  The same lots  of  virus were used to  infect  mice 
and target cells. 
Animals.  3-wk-old BALB/c mice were obtained from the National Institutes  of  Health Small 
Animal Section,  Bethesda, Md. 
Immunization of  Mice.  Mice were immunized by either:  (a) intranasal infection  with 10  a.s 
egg-infectious  doses (EIDso)  of the A/PR/8/34 (HON1), A/Scotland/840/74 (H3N2) or A/England/ 
42/72 (H3N2) strains  of  influenza virus;  or (b)  intraperitoneal  inoculation  of  formalin-inactivated 
whole virus containing 70 chick-cell  agglutinating units/dose  and two booster doses of  live  virus 
(108  EID~o) at 3-wk intervals.  These were first  administered intranasally,  and then intravenously 
for the A/Port Chalmers/1/73 (H3N2), A/Victoria/3/75 (H3N2) and the B/Hong Kong/5/72 virus 
strains. 
Complement and Sera.  Mice were bled from the heart,  the blood was quickly clotted,  and the 
sera were pooled and immediately frozen in aliquots at -70°C. Sera from nonimmune BALB/c 
mice served as the source of  complement (C')  in these studies because guinea pig and rabbit C' 
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were tested and showed high levels  of nonspecific  lysis.  Test sera from inf~ted or immunized 
animals were prepared in a similar  manner. Heat inactivation  for  30 rain  at 56°C removed all  C' 
activity. 
Antibody  Assays.  The  titer of hemagglutination-inhibition  (HI) antibodies was  deter- 
mined by standard microtiter  methods after  removal of  nonspecific  inhibitors  (12).  Neutralizing 
antibodies were determined by a plaque assay (13)  in canine kidney cells  (Flow Laboratories, 
Inc., Rockville, Md.) after  preincubation  of serially  diluted serum samples with 50 plaque- 
forming units  of  virus,  and 50% plaque-neutralizing antibody titers  were then calculated.  Neura- 
minidase inhibiting  antibodies  were detected using standard methods (14). 
Cytolytic Antibody  Assay.  A  syngeneic target cell system developed for assaying T-cell 
cytotoxicity  was utilized  for  assaying C'-dependent, antibody-mediated lysis  of  influenza-infected 
cells (3). Monolayers  of second-passage  BALB/c  mouse  kidney cells were infected with a 
multiplicity of infection  which resulted in ----90%  of the cells  showing membrane  fluorescence 
after 18 h of incubation. This was determined by indirect  immunofluorescent staining with a 
specific  mouse anti-influenzaantisera and fluorescein-conjugated  goat anti-mouse immunoglobu- 
fin. Infected and control target cells  were trypsinized,  labeled with Na~SICrO4 (New England 
Nuclear,  Boston, Mass.), washed, and 5  ×  104 cells  in 0.1 ml of Eagle's minimal essential 
medium containing 10% fetal  calf  serum was put into  16 x 125-mm tissue  culture tubes (model 
3033;  Falcon Plastics,  Div. of  BioQuest, Oxnard, Calif.).  Test sera (0.2  ml) and C' (0.1  ml of  a 1:4 
dilution)  were then added and  duplicate  samples were incubated  for  2 h at  36°C. Additional tubes 
contained target cells  plus 0.3 ml of  a 10% solution  of Brij  detergent (Sigma Chemical Co.,  St. 
Louis, Mo.) to  determine the maximum  released.  Radioactivity  in supernates and cell  sediments 
was determined separately in a Searle gamma  counter (Searle  Radiographics, Inc.,  Des Plalnes, 
Ill.)  and the percent of  51Cr released was calculated.  The percent of specific  immune lysis  (SIL) 
was derived from the following  formula: 
% SIL = (% lysis  by Ab + C') - % lysis  by C' only 
% maximum  lysis  - % lysis  by C' only 
Background 51Cr  released  by infected  and noninfected cells  with medium with C' was usually 15- 
30%. 
Results 
Initially,  the  ability  to  detect  cytotoxic  antibodies  was  evaluated  using 
several pools of sera which had relatively high titers of HI  (1:128-1:512)  and 
virus-neutralizing  (1:256-1:1,028)  antibodies  obtained  from  mice  immunized 
and  boostered  with  A/Port  Chalmers  virus.  These  hyperimmune  nonheat- 
inactivated  sera lysed infected,  but not control target  cells.  Heated immune 
sera or nonimmune,  nonheated sera did not lyse infected cells. The addition of 
fresh  non_heated,  nonimmune  mouse  serum  to  the  heat-inactivatod  immune 
mouse serum restored the lytic capability of the immune sera. A 1:4 dilution of 
nonimmune  mouse sera was subsequently used as the source of C'  in further 
testing of these immune sera.  The  50% cytolytic antibody titer of four serum 
pools  of similarly  prepared  hyperimmune  sera  varied  less  than  twofold  in 
repeated assays. This reproducibility was in the same range  as that obtained 
with neutralization or HI assays performed on the same sera. The 50% cytolytic 
antibody titers were generally lower than  neutralizing  antibodies  (P  <  0.01) 
and the HI titers (P <  0.05) of these sera. 
After the reproducibility of the assay had been established,  an  experiment 
was performed to study the development of cytolytic antibodies during primary 
infection with a  mouse-adapted  (MRC-9) A/Port Chalmers  virus.  Fig.  1 illus- 
trates  the rapid  replication  of virus in the lungs  of infected mice.  By day 4, 
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FIG.  1.  Antibody production after intranasal infection with 5 mean lethal doses of A/Port 
Chalmers  virus  in  3-wk-old  BALB/c  mice.  The  reciprocal  HI  (O),  cytolytic  ([~),  and 
neutralizing (/x) antibody titers represent the means of  four individual assays performed on 
serum pools obtained from 10  mice sacrificed on the day indicated after infection. The 
pulmonary virus titers (e) are indicated as EIDso/0.1  ml. 
infectious virus could be detected on day 8. No antibodies were detectable until 
day 8 by virus neutralization,  hemagglutination-inhibition,  or cytolytic assays. 
All three  antibody titers  then  began to rise in  parallel,  reaching  peak titers 
around day 30, and they were lower when tested on day 60. 
Mice were also immunized intraperitoneally with formalin-inactivated intact 
A/Port Chalmers vaccine (MRC-11; Merrell-National  Laboratories, Cincinnati, 
Ohio)  and  their  antibody responses  were measured  by the  same techniques. 
The cytolytic antibodies were detected as early as day 8 and rose in parallel 
with the viral-neutralizing  and HI antibodies through day 30. Ratios of cytolytic 
to  neutralizing  antibody  titers  appeared  to  be  similar  to  those  obtained  in 
naturally infected mice. 
The  specificity  of the  cytolytic  C'-dependent  antibody  response  was  then 
evaluated  by testing  sera  of mice  after  immunization.  The  upper  portion  of 
Table  I  shows the  specific  antibody  responses  to two  influenza  A  viruses  of 
different  subtypes  (HON1  and  H3N2)  and  to  influenza  B  virus.  The  results 
indicated that the cytolytic antibody response was specific for the virus subtype 
in a  way that  was comparable to the HI response in these same mice.  Cross- 
reactivity was observed (lower part of Table I) when mice were infected with 
one of four different members of the H3N2 subtype isolated between 1972 and 
1975.  These viruses share the  same major hemagglutinin  and neuraminidase 
(H3N2) on their surfaces, but there has been some slight antigenic drift of the 
hemagglutinin  antigen of these strains.  The data in the lower portion of Table 
I show that  cross-reactivity was generally observed with immune mouse sera 
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TABLE  I 
Specificity of Cytolytic  C'-Dependent Antibodies 
Experi-  Immunizing virus 
ment 
Antibody titor  on target cells  infected with: 
B/Hong  A/PR/8  A/Port  A/Eng-  A/Scot- 
Kong  Chalmers  land  land 
A/Victoria 
B/Hong Kong/5/72  13 (32)*  <8 (<8)  <8 (<8) 
A/PR/8/34 (HONI)  <8 (<8)  31 (64)  <8 (<8) 
&]Port Chalmers/5/73 (H3N2)  <8 (<8)  <6 (<8)  27 (256) 
A/Port Chalmers/1/73  (H3N2)  43  (512)  32 (512)  30 (128)  33 (256) 
A/England/42/72  (H3N2)  12  (16)  25 f128)  18 (16)  9 (16) 
A/Scotland/840/74  (H3N2)  17  (16)  23 (64)  24/64)  23 (32) 
A/Victoria/3/75  (H3N2)  26  (256)  12 (512)  18 (256)  26 /512) 
* Reciprocal  of cytolytic  antibody titer  (reciprocal  of HI antibody titer). 
TABLE II 
Hemagglutinin Specificity  of Antiserum  to A/Port Chalmers 
(H3N2) Virus 
Virus used to infect target .cells 
Antibody titer 
Hemmagglutina- 
Cytolytic*  tion inhibitions 
A/Port Chalmers/1/73  (H3N2)  80.4  512 
A/Victoria/3/75  (H3N2)  42.8  128 
A/Japan/170/62  (H2N2)  <8  <8 
A/PR/8/34 (HON1)  <8  <8 
A/Equine-I Detroit/3/65  (HeqlNeql)  <8  <8 
Recombinant  (HeqlN2)  <8  <8 
Recombinant  (H3Neql)  23.  I  256 
* Expreased as the reciprocal of the 50% cytolytic  antibody titer. 
$ Reciprocal  of the serum HI antibody titer. 
inhibition techniques.  Thus,  the specificity  of the cytolytic  C'-dependent anti- 
body appears to be similar to that of the HI antibody. 
Further evaluation of the specificity of the cytolytic response was performed 
by  assaying  an  immune  A/Port  Chalmers  (MRC-9)  serum  against  several 
influenza  A  virus  strains  with  different  hemagglutinin  and  neuraminidase 
surface  antigens.  This serum contained antibodies to both the hemagglutinin 
(1:512)  and the neuraminidase  (1:128)  of A/Port Chalmers virus as determined 
by standard HI and neuraminidase-inhibiting  assays.  Table II shows that the 
antiserum lysed only cells infected with strains containing the same hemagglu- 
tinin (H3) regardless of the neuraminidase content. In contrast, this serum did 
not lyse  cells  infected  with  strains  containing  the  same  neuraminidase  (N2), 
but those having a  different hemagglutinin.  Furthermore,  this serum did not 
lyse cells infec.ted with the A/PR/8/34 (HON1) used to prepare this recombinant 
virus, demonstrating that the cytolytic specificity is not determined by common 
internal  antigens  shared by type A  influenza viruses such as nucleocapsid  or 
matrix proteins. 
Discussion 
The results reported in this paper indicate that there is a  readily detectable 
cytolytic antibody response to influenza infection. These antibodies are induced 
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Cytolytic antibodies can be detected soon after infection or immunization, and 
they tend to parallel the production of antibodies detected by neutralization or 
hemagglutination techniques. 
The specificity of cytolytic antibodies appears to be primarily directed against 
the hemagglutinin of the virus.  There was no cross-reactive lysis by immune 
sera of target cells infected with influenza viruses of another type or subtype; 
there was,  however,  cross-reactivity within the  H3N2  subtype using viruses 
with minor differences in hemagglutinin antigens. In experiments with recom- 
binant viruses, it is clear that the hemagglutinin induces a cytolytic antibody 
response which could be detected on target cells infected with a virus containing 
the  same  hemagglutinin, regardless  of the  neuraminidase antigen present. 
These results indicate that there is a hemagglutinin-specific cytolytic antibody 
response to influenza infection. These observations parallel our recent observa- 
tions on the specificity of the cytotoxic T-lymphocyte response specific to the 
viral hemagglutinin after influenza infection and vaccination (3-5). 
Although  the  present  studies  do  not  address  the  in  vivo  roles  of these 
antibodies, their results are consistent with the long-recognized importance of 
hemagglutinin specificity in understanding the epidemiology of influenza. The 
present data support the importance of the hemagglutinin antigen by demon- 
strating a  specific antibody response which recognizes viral hemagglutinin on 
infected cells and binds C'. Antibody with C' may speed lysis of infected cells 
or act indirectly by releasing chemotactic factors which attract phagocytic cells 
during acute infection (15). These immunological reactions may be immuno- 
pathological (8) as well as beneficial to the host. The present assay, as well as 
the recently described assay for the specific cytotoxic cell response,  may aid 
future investigations of the  host response  and mechanisms of recovery from 
influenza. 
Received for publication 26 September 1977. 
References 
1.  Schild, G. C. 1975. The antigens of the influenza viruses. In Influenza, the Viruses 
and the Disease. C. H. Stuart-Harris and G. C. Schild, editors. Publishing SCiences 
Group, Inc., Littleton, Mass. 53. 
2.  Schulze, I. T. 1975. The biologically active proteins of influenza virus: the hemagglu- 
tinin. In  The Influenza Viruses  and Influenza.  E.  D.  Kilbourne,  editor.  Academic 
Press Inc., New York. 53. 
3.  Ennis, F. A.,  W. J.  Martin, M. W. Verbonitz,  and G. M. Butchko.  1977. Specific 
studies  on  cytotoxic thymus derived  lymphocytes  reactive with  influenza virus 
infected cells: evidence for dual recognition of  H-2 and viral hemagglutinin antigens. 
Proc. Natl. Acad. Sci.  U. S. A. 74:3006. 
4.  Ennis,  F.  A.,  W.  J.  Martin, and M.  W.  Verbonitz.  1977. Hemagglutinin-specific 
cytotoxic T-cell response during influenza infection. J. Exp. Med.  146:893. 
5.  Ennis, F. A.,  W. J.  Martin, and M. W. Verbonitz.  1977. Cytotoxic T lymphocytes 
induced in mice with inactivated influenza virus vaccine. Nature  (Lond.).  269:478. 
6.  Effros, R. B., P. C. Doherty, W. E.  Gerhard, and J.  Bennink. 1977. Generation of 
both  cross-reactive  and virus-specific T-cell populations  after immunization with 
serologically distinct influenza A viruses. J. Exp. Med.  145:557. 270  VERBONITZ  ET  AL.  BRIEF  DEFINITIVE  REPORT 
7.  Zweerink,  H.  J.,  S.  A.  Courtneidge,  J.  J.  Skehel,  M.  J.  Crumpton,  and  B.  A. 
Askonas.  1977. Cytotoxic  T  cells  kill  influenza  virus  infected  cells  but  do  not 
distinguish between serologically distinct type A viruses. Nature (Lond.). 267:354. 
8.  Oldstone,  M.  B.  A.,  and  F.  J.  Dixon.  1971. Acute  viral  infection:  tissue  injury 
mediated by anti-viral antibody through a complement effector system. J. Immunol. 
107:1274. 
9.  Brier,  A.  M.,  C.  Wohlenberg,  J.  Rosenthal,  M.  Mage,  and  A.  L.  Notkins,  1971. 
Inhibition or enhancement of immunologic injury of virus-infected cells. Proc. Natl. 
Acad. Sci.  U. S. A. 68:3073. 
10.  Joseph,  B.  S.,  N.  R.  Cooper, and M.  B.  A.  Oldstone.  1975. Immunologic injury of 
cultured cells infected with measles virus. I. Role of IgG antibody and the alternative 
complement pathway. J. Exp. Med. 141:761. 
11.  Hicks,  J.  T.,  M.  J.  Klutch,  P.  Albrecht,  and  M.  M.  Frank.  1976. Analysis  of 
complement-dependent antibody-mediated lysis of target cells acutely infected with 
measles. J. Immunol.  117:208. 
12.  Tauraso,  N.  M.,  F.  A. Pedreira,  S.  L.  Spector,  and G.  M.  Bernier.  1971. Effect of 
various methods of removing non-specific inhibitors to virus hemagglutination upon 
serum proteins and immunoglobulins. Arch. Gesamte Virusforsch.  34:214. 
13.  Appleyard,  G.,  and  H.  B.  Maber.  1974. Plaque  formation by influenza  viruses in 
presence of trypsin. J. Gen. Virol.  25:351. 
14.  Advanced laboratory techniques  for influenza diagnosis.  1975. Immunology Series 
No.  6  Procedural  Guide.  U.  S.  Department  of Health,  Education,  and  Welfare, 
Center for Disease Control, Atlanta, Georgia. 107. 
15.  Ward, P. A., S. Cohen, and T. D. Flanagan.  1972. Leukotactic factors elaborated by 
virus-infected tissues. J. Exp. Med.  135:1095. 